AtaiBeckley (ATAI) Non-Current Deferred Tax Liability (2022 - 2025)

AtaiBeckley (ATAI) reported Non-Current Deferred Tax Liability of $12.0 million for Q4 2022.

AtaiBeckley (ATAI) Non-Current Deferred Tax Liability (2022 - 2025) Analysis & Trends

AtaiBeckley's Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $17.8 million for Q4 2025.

For the quarter ending Q4 2022, Non-Current Deferred Tax Liability changed N/A year-over-year to $12.0 million; the trailing twelve-month figure through Dec 2022 stood at $12.0 million (changed N/A YoY), and the FY2022 full-year result was $12.0 million, changed N/A from the prior year.
Non-Current Deferred Tax Liability rose to $17.8 million in Q4 2025 per ATAI's latest filing, from $6.9 million in the prior quarter.
Across five years, Non-Current Deferred Tax Liability topped out at $17.8 million in Q4 2025 and bottomed at $6.9 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	AtaiBeckley	2.56 Bn	2.56 Bn	-

Download Data